Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Hemispherian AS logo — Hemispherian is a biotechnology company developing new treat...

Hemispherian AS

Hemispherian is a biotechnology company developing new treatments for the most aggressive types of cancer.

Founded 2015 Norway Norway 10 employees Grant Total: $84.80M Biotechnology, Health Care

General Information

Company Name Hemispherian AS
Founded Year 2015
Location Norway Norway
Employees 10
Industries Biotechnology, Health Care
Funding Stage Grant
Social

BounceWatch is an independent company data service, not affiliated with Hemispherian AS. To contact Hemispherian AS, visit hemispherian.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Hemispherian AS compare?

A PDF of Hemispherian AS and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Hemispherian AS soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Hemispherian AS

Hemispherian AS is a biotechnology company based in Norway, founded in 2015. Their mission is to develop new treatments for the most aggressive types of cancer, with a focus on creating a new drug to treat Glioblastoma Multiforme (GBM).

They aim to significantly increase life expectancy for patients, improve patient comfort, and generally increase the overall survival rates for GBM patients. The company recently secured a kr16.00M investment, in the form of a grant from the Norwegian Research Council on 15 December 2023.

Hemispherian's dedication to addressing critical medical needs through biotechnology places them at the forefront of innovation in the healthcare industry. With their focus on tackling challenging medical conditions and their recent financial backing, they are well-positioned to make a significant impact in the field of cancer treatment.

Business keywords: cancer treatment, Glioblastoma Multiforme, drug development, life expectancy improvement, patient comfort, survival rates, aggressive cancer, oncology, innovation, clinical research, precision medicine

Funding Rounds & Investors (9)

View All
Funding Stage Amount Investors Lead Investors Date
Grant kr16.00M 1
Norwegian Research Council
15 Dec 2023
Series A kr30.00M 4
Kistefos Venture Capital Kvantia
Kistefos Venture Capital, Kvantia +2
24 Nov 2022
Grant €2.50M 2
European Innovation Council
European Innovation Council, EIC Accelerator
19 Oct 2022
Venture Round €7.50M 2
European Innovation Council
European Innovation Council, EIC Accelerator
19 Oct 2022
Seed Round kr12.50M 1
Meneldor
03 May 2022
Convertible Note Undisclosed 1
BIF Partners
BIF Partners
01 Apr 2022
Seed Round $400.00K 2
Investinor
Investinor, PAACS Invest AS
04 Jan 2021
Grant kr14.60M -
02 Nov 2020
Grant kr1.30M -
12 Jun 2020

Hemispherian AS Alternatives & Competitors

View All Alternatives
Hemispherian AS vs
Kintara Therapeutics, Inc. NASDAQ: KTRA
Kintara Therapeutics, Inc. NASDAQ: KTRA United States

Seeking New Horizons for Cancer Patients

Grant
8 employees
Biotechnology, Health Care
Hemispherian AS vs
Notable
Notable United States

Notable is a mission-driven company transforming the way cancer is treated

33 employees
Biotechnology, Health Care
Hemispherian AS vs
Tradewind BioScience
Tradewind BioScience United States

Innovative therapeutics for the most aggressive cancers

Seed
5 employees
Biotechnology, Health Care
View all alternatives

FAQ About Hemispherian AS

Hemispherian is a biotechnology company developing new treatments for the most aggressive types of cancer.
Hemispherian AS was founded in 2015.
Hemispherian AS is headquartered in Norway.
Hemispherian AS operates in Biotechnology and Health Care. Its work centres on cancer treatment, Glioblastoma Multiforme, drug development and life expectancy improvement.
Hemispherian AS has approximately 10 employees.
Hemispherian AS has completed 9 funding rounds, raising a total of $84.80M. The latest funding stage is Grant.
Top alternatives and competitors to Hemispherian AS include Kintara Therapeutics, Inc. NASDAQ: KTRA, Notable, Tradewind BioScience, Alpheus Medical, Inc, iOnctura. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Hemispherian AS and Kintara Therapeutics, Inc. NASDAQ: KTRA are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Hemispherian AS, https://bouncewatch.com/company/hemispherian-as, updated 19 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout